A Phase 2 interventional study of Part A: RPL554 and Placebos in COPD, sponsored by Verona Pharma plc. Completed at 2 sites in United Kingdom. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-09-21.
Sponsored by Verona Pharma plc (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 2 under way, 1 of them phase 3. ensifentrine · Pulmonary Disease, Chronic Obstructive.
Among the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, this one is the 10th largest by enrollment, is the only one that started in 2019, is one of 8 in phase 2, and was the 6th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →1 of the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive is open now, in 1 country. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States
Ages 40–80
By country, each count listing its studies:
ensifentrine: first FDA approval 2024 (OHTUVAYRE). What it is approved for, and how studies give it, is on its page →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 79 across the 15 interventional studies. Of the 13 that completed or were terminated, 7 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 4 most frequent:
This study is registered under Verona Pharma plc, one of the names counted as Merck & Co., Inc. Under that name alone:
Verona Pharma plc is the lead sponsor of 13 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc: 1 open now, 3 under way, 1 of them phase 3. Of 23 finished, 15 (65%) have results posted.
Among the 26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc, this one is the 18th largest by enrollment, is one of 2 that started in 2019, is one of 18 in phase 2, and was the 17th registered.
Merck & Co., Inc’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2002.
1 of the studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05270525Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAEffect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207) | 2027-03-01 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Among Merck & Co., Inc’s 26 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate 5 doses of RPL554 and placebo, administered by pressurized metered dose inhaler (pMDI), in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
The study will consist of two parts. Part A is a parallel group, placebo-controlled single dose study to ascertain the Pharmacokinetics (PK) profile, safety and bronchodilator effect of a single dose of RPL554 administered via pMDI. Five of the 6 treatment arms will be double-blind and one will be single-blind (due to the different number of capsules administered). Part B is a 7-day placebo-controlled, complete block cross-over, repeat dose study to assess the bronchodilator effect of repeat doses of RPL554 delivered via pMDI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A: Patients receive 1 dose of either RPL554 100mcg via metered dose inhaler. Part B: not applicable
Drug: Part A: RPL554 · Drug: Placebos
Part A: Patients receive 1 dose of RPL554 300mcg via metered dose inhaler. Part B: Patients receive repeat doses of RPL554 300mcg via metered dose inhaler in crossover fashion.
Drug: Part A: RPL554 · Drug: Placebos · Drug: Part B: RPL554
Part A: Patients receive 1 dose of RPL554 1000mcg via metered dose inhaler. Part B: Patients receive repeat doses of RPL554 3000mcg via metered dose inhaler in crossover fashion.
Drug: Part A: RPL554 · Drug: Placebos · Drug: Part B: RPL554
Part A: Patients receive 1 dose of either RPL554 3000mcg via metered dose inhaler. Part B: Patients receive repeat doses of RPL554 3000mcg via metered dose inhaler in crossover fashion.
Drug: Part A: RPL554 · Drug: Placebos · Drug: Part B: RPL554
Part A: Patients receive 1 dose of either RPL554 6000mcg via metered dose inhaler. Part B: not applicable
Drug: Part A: RPL554 · Drug: Placebos
Part A: Patients receive 1 dose of RPL554 placebo via metered dose inhaler. Part B: Patients receive repeat doses of RPL554 placebo via metered dose inhaler in crossover fashion.
Drug: Part A: RPL554 · Drug: Placebos
Single dose RPL554 via metered dose inhaler.
Also known as: Part A
Part A: Single dose placebo via metered dose inhaler. Part B: Repeat doses of placebo via metered dose inhaler in crossover fashion. One dose administered twice daily over 7 days.
Part B: Repeat doses via metered dose inhaler in crossover fashion. One dose administered twice daily over 7 days.
Also known as: Part B
Part A: Pharmacokinetic Parameter AUC0-12
Area under the curve from 0 to 12 hours after single dose drug administration.
Time frame: Day 1
Part A: Pharmacokinetic Parameter Cmax
Pharmacokinetic Parameter Cmax after a Single Dose
Time frame: Day 1
Part A: Pharmacokinetic Parameter AUC0-t
Area under the curve at maximum concentration 0-24 hrs after single dose drug administration
Time frame: Day 1
Part A: RPL554 Plasma Pharmacokinetic Parameter (Half-life)
RPL554 Plasma Pharmacokinetics concentration after single dose
Time frame: Day 1
Part B: Change From Baseline in Peak FEV1 (Over 4 Hours) on Day 7
Change from Baseline FEV1 to Peak FEV1 (over 4 hours) after morning dosing on Day 7
Time frame: Day 7
Part A: Change From Baseline in Peak FEV1 (Over 4 Hours) After 1 Dose
Change from Baseline FEV1 to Peak FEV1 (over 4 hours) After Single Dose
Time frame: Day 1
Part A: Change From Baseline in Average FEV1 (Over 4 Hours) After 1 Dose
Change from Baseline FEV1 to Average FEV1 (over 4 hours) After Single Dose
Time frame: Day 1
Part A: Change From Baseline in Average FEV1 (Over 12 Hours) After 1 Dose
Change from Baseline FEV1 to Average FEV1 (over 12 hours) After Single Dose
Time frame: Day 1
Part A: Safety and Tolerability / Hematology Safety Assessments
Number of patients with treatment-emergent hematology abnormal laboratory assessments
Time frame: 1 day
Part A: Safety and Tolerability / Blood Chemistry Safety Assessments: Number of Patients With Treatment-emergent Blood Chemistry Abnormal Laboratory Assessments
Number of patients with treatment-emergent blood chemistry abnormal laboratory assessments
Time frame: 1 day
Part A: Safety and Tolerability / Urinalysis Safety Assessments: Number of Patients With Treatment-emergent Urinalysis Abnormal Laboratory Assessments
Number of patients with treatment-emergent urinalysis abnormal laboratory assessments
Time frame: 1 day
Part A: Safety and Tolerability / Supine Vitals Signs - Pulse Rate
Number of patients with treatment-emergent abnormal vital signs (pulse rate in bpm)
Time frame: Start of treatment to day 1
Part A: Safety and Tolerability / Supine Vitals Signs - Blood Pressure
Number of patients with treatment-emergent abnormal vital signs (blood pressure in mm Hg)
Time frame: Start of treatment to day 1
Part A: Safety and Tolerability / ECG - QTcF
Number of patients with treatment-emergent abnormal ECG parameters, QTcF in msec
Time frame: Start of treatment to day 1
Part A: Safety and Tolerability / ECG - Heart Rate
Number of patients with treatment-emergent abnormal ECG parameters, heart rate in bpm
Time frame: Start of treatment to day 1
Part B: Change From Baseline in Average FEV1 (Over 4 Hrs) After 7 Days
Change from baseline in average FEV1 (over 4 hours) on Day 7 after morning dose
Time frame: Day 7
Part B: Change From Baseline in Average FEV1 (Over 12 Hours) After 7 Days
Change from baseline FEV1 in average FEV1 (over 12 hours) on Day 7 after morning dose
Time frame: Day 7
Part B: Change From Baseline in Trough FEV1 After 7 Days
Change from Baseline FEV1 to Morning Trough FEV1 on Day 7 after morning dose
Time frame: Day 7
Part B: Change From Baseline in Peak FEV1 (Over 4 Hours) After 1st Dose
Change from baseline FEV1 in peak FEV1 (over 4 hours) after first dose
Time frame: Day 1
Part B: Change From Baseline in Average FEV1 (Over 4 Hours) After 1st Dose
Change from baseline FEV1 in average FEV1 (over 4 hours) on Day 1
Time frame: Day 1
Part B: Change From Baseline in Average FEV1 (Over 12 Hours) After 1st Dose
Change from baseline FEV1 in average FEV1 (over 12 hours) on Day 1
Time frame: Day 1
Part B: RPL554 Plasma Pharmacokinetic Parameter (Onset of Action)
Determination of onset of action (\>10% increase in FEV1 from pre- to post-first dose, censored at 120 minutes) on Day 1
Time frame: Day 1
Part B: Safety and Tolerability / Hematology Safety Assessments
Number of patients with treatment-emergent hematology abnormal laboratory assessments
Time frame: 1 day
Part B: Safety and Tolerability / Blood Chemistry Safety Assessments
Number of patients with treatment-emergent blood chemistry abnormal laboratory assessments
Time frame: 1 day
Part B: Safety and Tolerability / Urinalysis Safety Assessments
Number of patients with treatment-emergent urinalysis abnormal laboratory assessments
Time frame: 1 day
Part B: Safety and Tolerability / Supine Vital Signs - Pulse Rate
Number of patients with treatment-emergent abnormal vital signs (pulse rate in bpm)
Time frame: Start of treatment to day 1
Part B: Safety and Tolerability / Supine Vital Signs - Blood Pressure
Number of patients with treatment-emergent abnormal vital signs (blood pressure in mm Hg)
Time frame: Start of treatment to day 1
Part B: Safety and Tolerability / ECG - QTcF
Number of patients with treatment-emergent abnormal ECG parameters, QTcF in msec
Time frame: Start of treatment to day 70
Part B: Safety and Tolerability / ECG - Heart Rate
Number of patients with treatment-emergent abnormal ECG parameters, heart rate in bpm
Time frame: Start of treatment to day 70
40 subjects enrolled for Part A and eligible to continue into Part B.
| Milestone | 0.10 mg/Part A | 0.30 mg/Part A | 1 mg/Part A | 3 mg/Part A | 6 mg/Part A | Placebo/Part A | Seq 1/Part B | Seq 2/Part B | Seq 3/Part B | Seq 4/Part B |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 7 | 6 | 7 | 7 | 7 | 0 | 0 | 0 | 0 |
| Completed | 6 | 7 | 6 | 7 | 7 | 7 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | 0.10 mg/Part A | 0.30 mg/Part A | 1 mg/Part A | 3 mg/Part A | 6 mg/Part A | Placebo/Part A | Seq 1/Part B | Seq 2/Part B | Seq 3/Part B | Seq 4/Part B |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 7 | 7 | 6 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 | 6 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
Area under the curve from 0 to 12 hours after single dose drug administration.
| h*pg/mL | 0.10 mg | 0.30 mg | 1 mg | 3 mg | 6 mg |
|---|---|---|---|---|---|
| Part A: Pharmacokinetic Parameter AUC0-12 | 175 ± 96.7 | 611 ± 183 | 1550 ± 443 | 5860 ± 3120 | 9360 ± 8100 |
Pharmacokinetic Parameter Cmax after a Single Dose
| pg/mL | 0.10 mg | 0.30 mg | 1 mg | 3 mg | 6 mg |
|---|---|---|---|---|---|
| Part A: Pharmacokinetic Parameter Cmax | 39.4 ± 16.4 | 138 ± 40.9 | 467 ± 57.8 | 1520 ± 1050 | 2360 ± 1430 |
Area under the curve at maximum concentration 0-24 hrs after single dose drug administration
| h*pg/mL | 0.10 mg | 0.30 mg | 1 mg | 3 mg | 6 mg |
|---|---|---|---|---|---|
| Part A: Pharmacokinetic Parameter AUC0-t | 208 ± 119 | 692 ± 229 | 1680 ± 559 | 6800 ± 3770 | 10800 ± 10100 |
RPL554 Plasma Pharmacokinetics concentration after single dose
| h | 0.10 mg | 0.30 mg | 1 mg | 3 mg | 6 mg |
|---|---|---|---|---|---|
| Part A: RPL554 Plasma Pharmacokinetic Parameter (Half-life) | 6.31 ± 5.18 | 5.32 ± 3.36 | 3.47 ± 1.44 | 5.62 ± 1.7 | 4.44 ± 2.03 |
Change from Baseline FEV1 to Peak FEV1 (over 4 hours) after morning dosing on Day 7
| L | 0.30 mg | 1 mg | 3 mg | Placebo |
|---|---|---|---|---|
| Part B: Change From Baseline in Peak FEV1 (Over 4 Hours) on Day 7 | 0.189 ± 0.1624 | 0.261 ± 0.1597 | 0.310 ± 0.1511 | -0.016 ± 0.1485 |
Change from Baseline FEV1 to Peak FEV1 (over 4 hours) After Single Dose
| L | 0.10 mg | 0.30 mg | 1 mg | 3 mg | 6 mg | Placebo |
|---|---|---|---|---|---|---|
| Part A: Change From Baseline in Peak FEV1 (Over 4 Hours) After 1 Dose | 0.133 ± 0.1144 | 0.264 ± 0.1012 | 0.255 ± 0.0994 | 0.332 ± 0.2095 | 0.477 ± 0.1469 | 0.086 ± 0.0694 |
Change from Baseline FEV1 to Average FEV1 (over 4 hours) After Single Dose
| L | 0.10 mg | 0.30 mg | 1 mg | 3 mg | 6 mg | Placebo |
|---|---|---|---|---|---|---|
| Part A: Change From Baseline in Average FEV1 (Over 4 Hours) After 1 Dose | 0.058 ± 0.0889 | 0.161 ± 0.0650 | 0.153 ± 0.0653 | 0.240 ± 0.1677 | 0.334 ± 0.1147 | -0.011 ± 0.0805 |
Change from Baseline FEV1 to Average FEV1 (over 12 hours) After Single Dose
| L | 0.10 mg | 0.30 mg | 1 mg | 3 mg | 6 mg | Placebo |
|---|---|---|---|---|---|---|
| Part A: Change From Baseline in Average FEV1 (Over 12 Hours) After 1 Dose | 0.018 ± 0.0643 | 0.061 ± 0.0429 | 0.010 ± 0.0408 | 0.121 ± 0.1321 | 0.190 ± 0.1053 | -0.031 ± 0.0740 |
Number of patients with treatment-emergent hematology abnormal laboratory assessments
Results for this outcome have not been posted.
Number of patients with treatment-emergent blood chemistry abnormal laboratory assessments
Results for this outcome have not been posted.
Number of patients with treatment-emergent urinalysis abnormal laboratory assessments
Results for this outcome have not been posted.
Number of patients with treatment-emergent abnormal vital signs (pulse rate in bpm)
Results for this outcome have not been posted.
Number of patients with treatment-emergent abnormal vital signs (blood pressure in mm Hg)
Results for this outcome have not been posted.
Number of patients with treatment-emergent abnormal ECG parameters, QTcF in msec
Results for this outcome have not been posted.
Number of patients with treatment-emergent abnormal ECG parameters, heart rate in bpm
Results for this outcome have not been posted.
Change from baseline in average FEV1 (over 4 hours) on Day 7 after morning dose
| L | 0.30 mg | 1 mg | 3 mg | Placebo |
|---|---|---|---|---|
| Part B: Change From Baseline in Average FEV1 (Over 4 Hrs) After 7 Days | 0.083 ± 0.1223 | 0.161 ± 0.1686 | 0.206 ± 0.1470 | -0.095 ± 0.1702 |
Change from baseline FEV1 in average FEV1 (over 12 hours) on Day 7 after morning dose
| L | 0.30 mg | 1 mg | 3 mg | Placebo |
|---|---|---|---|---|
| Part B: Change From Baseline in Average FEV1 (Over 12 Hours) After 7 Days | 0.008 ± 0.1421 | 0.075 ± 0.1472 | 0.085 ± 0.1411 | -0.112 ± 0.1662 |
Change from Baseline FEV1 to Morning Trough FEV1 on Day 7 after morning dose
| L | 0.30 mg | 1 mg | 3 mg | Placebo |
|---|---|---|---|---|
| Part B: Change From Baseline in Trough FEV1 After 7 Days | -0.051 ± 0.1254 | -0.017 ± 0.1783 | 0.013 ± 0.1631 | -0.097 ± 0.1389 |
Change from baseline FEV1 in peak FEV1 (over 4 hours) after first dose
| L | 0.30 mg | 1 mg | 3 mg | Placebo |
|---|---|---|---|---|
| Part B: Change From Baseline in Peak FEV1 (Over 4 Hours) After 1st Dose | 0.253 ± 0.0772 | 0.311 ± 0.1532 | 0.337 ± 0.1108 | 0.079 ± 0.0914 |
Change from baseline FEV1 in average FEV1 (over 4 hours) on Day 1
| L | 0.30 mg | 1 mg | 3 mg | Placebo |
|---|---|---|---|---|
| Part B: Change From Baseline in Average FEV1 (Over 4 Hours) After 1st Dose | 0.144 ± 0.0762 | 0.204 ± 0.1162 | 0.224 ± 0.0905 | -0.017 ± 0.1284 |
Change from baseline FEV1 in average FEV1 (over 12 hours) on Day 1
| L | 0.30 mg | 1 mg | 3 mg | Placebo |
|---|---|---|---|---|
| Part B: Change From Baseline in Average FEV1 (Over 12 Hours) After 1st Dose | 0.047 ± 0.0914 | 0.102 ± 0.1306 | 0.085 ± 0.0659 | -0.058 ± 0.1444 |
Determination of onset of action (\>10% increase in FEV1 from pre- to post-first dose, censored at 120 minutes) on Day 1
| mins | 0.30 mg | 1 mg | 3 mg |
|---|---|---|---|
| Part B: RPL554 Plasma Pharmacokinetic Parameter (Onset of Action) | 37.0 (3 to 120) | 27.5 (5 to 120) | 19.0 (5 to 91) |
Number of patients with treatment-emergent hematology abnormal laboratory assessments
Results for this outcome have not been posted.
Number of patients with treatment-emergent blood chemistry abnormal laboratory assessments
Results for this outcome have not been posted.
Number of patients with treatment-emergent urinalysis abnormal laboratory assessments
Results for this outcome have not been posted.
Number of patients with treatment-emergent abnormal vital signs (pulse rate in bpm)
Results for this outcome have not been posted.
Number of patients with treatment-emergent abnormal vital signs (blood pressure in mm Hg)
Results for this outcome have not been posted.
Number of patients with treatment-emergent abnormal ECG parameters, QTcF in msec
Results for this outcome have not been posted.
Number of patients with treatment-emergent abnormal ECG parameters, heart rate in bpm
Results for this outcome have not been posted.
Collected over Part A: 24 hours. Part B: Approximately 70 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.10 mg/Part A | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| 0.30 mg/Part A | 0/7 (0%) | 0/7 (0%) | 1/7 (14.3%) |
| 1 mg/Part A | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| 3 mg/Part A | 0/7 (0%) | 0/7 (0%) | 2/7 (28.6%) |
| 6 mg/Part A | 0/7 (0%) | 0/7 (0%) | 4/7 (57.1%) |
| Placebo/Part A | 0/7 (0%) | 0/7 (0%) | 2/7 (28.6%) |
| Part B/0.30 mg | 0/24 (0%) | 0/24 (0%) | 3/24 (12.5%) |
| Part B/1 mg | 0/23 (0%) | 0/23 (0%) | 4/23 (17.4%) |
| Part B/3 mg | 0/23 (0%) | 0/23 (0%) | 2/23 (8.7%) |
| Part B/Placebo | 0/25 (0%) | 0/25 (0%) | 3/25 (12%) |
| Event | 0.10 mg/Part A | 0.30 mg/Part A | 1 mg/Part A | 3 mg/Part A | 6 mg/Part A | Placebo/Part A | Part B/0.30 mg | Part B/1 mg | Part B/3 mg | Part B/Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/6 | 0/7 | 1/6 | 1/7 | 2/7 | 1/7 | 1/24 | 1/23 | 0/23 | 0/25 |
| SyncopeNervous system disorders | 1/6 | 0/7 | 0/6 | 0/7 | 0/7 | 0/7 | 0/24 | 0/23 | 0/23 | 0/25 |
| COPDRespiratory, thoracic and mediastinal disorders | 1/6 | 0/7 | 0/6 | 0/7 | 0/7 | 0/7 | 0/24 | 0/23 | 0/23 | 1/25 |
| Dry throatRespiratory, thoracic and mediastinal disorders | 1/6 | 0/7 | 0/6 | 0/7 | 0/7 | 0/7 | 0/24 | 0/23 | 0/23 | 0/25 |
| NasopharyngitisInfections and infestations | 0/6 | 1/7 | 0/6 | 0/7 | 1/7 | 1/7 | 0/24 | 0/23 | 0/23 | 0/25 |
| RhinitisInfections and infestations | 0/6 | 0/7 | 0/6 | 0/7 | 1/7 | 0/7 | 0/24 | 0/23 | 0/23 | 0/25 |
| Upper respiratory tract infectionInfections and infestations | 0/6 | 0/7 | 0/6 | 0/7 | 0/7 | 1/7 | 0/24 | 0/23 | 0/23 | 0/25 |
| ContusionInjury, poisoning and procedural complications | 0/6 | 0/7 | 0/6 | 0/7 | 1/7 | 0/7 | 0/24 | 0/23 | 0/23 | 0/25 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 0/6 | 0/7 | 0/6 | 0/7 | 0/7 | 1/7 | 0/24 | 0/23 | 0/23 | 0/25 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 0/6 | 0/7 | 0/6 | 1/7 | 0/7 | 0/7 | 0/24 | 0/23 | 0/23 | 0/25 |
| Age, Continuous(years) | 0.10 mg | 0.30 mg | 1 mg | 3 mg | 6 mg | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 66.8 ± 4.92 | 71.4 ± 1.27 | 64.3 ± 7.87 | 67.1 ± 6.72 | 63.1 ± 8.71 | 64.4 ± 6.60 | 66.3 ± 6.67 |
| Sex: Female, Male(Participants) | 0.10 mg | 0.30 mg | 1 mg | 3 mg | 6 mg | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 2 | 4 | 2 | 3 | 2 | 3 | 16 |
| Male | 4 | 3 | 4 | 4 | 5 | 4 | 24 |
| Ethnicity (NIH/OMB)(Participants) | 0.10 mg | 0.30 mg | 1 mg | 3 mg | 6 mg | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 6 | 7 | 6 | 7 | 7 | 7 | 40 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 0.10 mg | 0.30 mg | 1 mg | 3 mg | 6 mg | Placebo | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 6 | 7 | 6 | 7 | 7 | 7 | 40 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | 0.10 mg | 0.30 mg | 1 mg | 3 mg | 6 mg | Placebo | Total |
|---|---|---|---|---|---|---|---|
| United Kingdom | 6 | 7 | 6 | 7 | 7 | 7 | 40 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2019 to primary completion in Dec 2020, 19 months.
Results were first posted in Jul 2022, 1 year 7 months after primary completion.
Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 19 months is above that.
Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ensifentrine
Pulmonary Disease, Chronic Obstructive →